A B S T R A C T The capacity for fixation and activation of hemolytic complement by polyclonal IgM rheumatoid factors (RF) isolated from sera of patients with rheumatoid arthritis and monoclonal IgM-RF isolated from the cryoprecipitates of patients with IgM-IgG mixed cryoglobulinemia was examined. RF mixed with aggregated, -reduced, and alkylated human IgG (Agg-R/AIgG) in the fluid phase failed to significantly reduce the level of total hemolytic complement, CHuo, or of individual complement components, Cl, C2, C3, and C5.
However, sheep erythrocytes (SRC) coated with Agg-R/A-IgG or with reduced and alkylated rabbit IgG anti-SRC antibody were hemolyzed by complement in the presence of polyclonal IgM-RF. Human and guinea pig complement worked equally well. The degree of hemolysis was in direct proportion to the hemagglutination titer of the RF against the same coated cells. Monoclonal IgM-RF, normal human IgM, and purified Waldenstrdm macroglobulins without antiglobulin activity were all inert.
Hemolysis of coated SRC by RF and complement was inhibited by prior treatment of the complement source with chelating agents, hydrazine, cobra venom factor, specific antisera to Clq, C4, C5, C6, or C8, or by heating at 560C for 30 min. Purified radiolabeled C4, C3, and C8 included in the complement source were bound to hemolysed SRC in direct proportion to the degree of hemolysis. These data indicate that polyclonal IgM-RF fix and activate complement via the classic pathway.
The system described for assessing complement fixation by isolated RF is readily adaptable to use with whole human serum.
INTRODUCTION
Complement participates in several biological reactions including immune cytolysis, phagocytosis, immune adherence, and chemotaxis (reviewed in references 1, 2). The role of complement in the pathogenesis of a number of human diseases including rheumatoid arthritis is not clear. The similarity of vascular lesions in rheumatoid arthritis (3) with those of the immune complex disease, experimental serum sickness (4), suggests that complement might play a role in the pathogenesis of rheumatoid vasculitis. The role of rheumatoid factor (RF) ' in rheumatoid arthritis is also unclear. Patients with highest titers of RF appear to be afflicted with more severe disease (5, 6) , and in experimental animals RF appear to augment tissue damage (7, 8) . Both RF and complement have been identified in the lesions of rheumatoid arthritis (9, 10) . Crucial to the elucidation of the role of RF and complement in the possible pathogenesis of rheumatoid arthritis is the question of whether complement with its potential for producing inflammation and alterations in vascular permeability is activated by RF. Although a number of recent studies (11) (12) (13) (14) (15) IgM-RF and was dialyzed against 0.15 M NaCl buffered to pH 7.4 with sodium phosphate (PBS) and concentrated by pervaporation. Only electrophoretically heterogeneous IgM was detected in these preparations when examined at a concentration of 4 mg/ml by immunoelectrophoresis employing antisera specific for IgM, IgG, and IgA. Homogeneous monoclonal IgM-RF were isolated from the sera of patients with mixed cryoglobulinemia by previously described methods (22, 23 Reduced and alkylated human IgG (R/A-IgG) was dialyzed against PBS and concentrated by pervaporation. This preparation was aggregated by incubation at 63°C for 20 min. The aggregated, reduced, and alkylated IgG (Agg-R/A-IgG) was isolated by gel filtration chromatography in PBS (23 tion with washed packed SRC at 0C. Lyophilized guinea pig serum purchased from Hyland Laboratories was reconstituted and absorbed with SRC as above. These absorbed human and guinea pig sera were stored in small aliquots at -70'C until they were used as the human complement (HuC) or guinea pig complement (GPC)
source.
Rabbit anti-SRC hemolysin, purchased from BBL, Division of Becton, Dickinson and Company, Cockeysville, Md., was separated into IgM and IgG fractions by Sephadex G-200 gel filtration. SRC were sensitized with IgM-hemolysin at four times the optimal sensitizing dose (IgM-EA) (33) .
Testing for complement fixation in the fluid phase by RF (V.) was done by adding 0.5 ml of each RF preparation and 200 jig Agg-R/A-IgG to HuC or GPC diluted in 0.15 M Veronal-buffered saline containing 0.1% gelatin and optimal Ca-+ and Mg-+ (GVB++) and incubating at 370C
for 60 min. The mixture was stored in convenient aliquots at -70'C. Residual CH68 was measured by a modification of Mayer's methods using IgM-EA in a total reaction volume of 1.5 ml (34). C1, C2, and C3 hemolytic activities were determined by published methods (34) (35) (36) . Hemolysis of sensitized SRC by RF preparations and complement utilized SRC sensitized with reduced and alkylated rabbit IgG-hemolysin (REA), or tanned SRC coated with Agg-R/A-IgG (tHEA). For preparation of the former cells, IgG-hemolysin isolated by gel filtration was reduced and alkylated (R/A-Hem) in order to diminish its complement-fixing activity. The hemagglutination titer of this preparation was 1: 40. SRC were sensitized in the same manner as with nonreduced and alkylated hemolysin. For preparation of tanned cells, washed SRC were suspended in pH 7.2 PBS and treated with 1: 80,000 diluted tannic acid by a modification of Boyden's method (37) . After tannic acid treatment, the cells were suspended to 2% (4 X 108/ ml) in pH 6.4 PBS and reacted with an equal volume of 200 Ag/ml of Agg-R/A-IgG.
For assessing complement-mediated hemolysis by RF, 0.2 ml of each RF preparation was incubated with REA or tHEA (2 x 108/ml) at 370C for 60 min and at 0C for 3 h and the cells were washed three times with GVB++. Serial dilutions of the absorbed HuC and GPC sources were incubated with the sensitized cells at 370C for 60 min and the degree of hemolysis was assessed by spectrophotometric measurement (412 nm) of hemoglobin released into the supernate.
Radiolabeled complement uptake. Purified HuC components C3, C4, and C8 were prepared by published methods (26) (27) (28) , trace labeled with '1I by the chloramine-T method (38) without loss of activity, and used for quantitative cell binding studies (39) . SRC sensitized with R/A-Hem were reacted with the RF preparations as described in the previous section. To a 1% suspension of these cells was added 0.1 ml of a 1: 5 dilution of HuC containing 1-6 X 106 cpm of 'I-labeled C3 (approximately 20 uig), C4 (approximately 5 jig), or C8 (approximately 5 gig). The suspension was incubated at 370C for 60 min, centrifuged, and an aliquot of the supernate removed for determination of the degree of hemolysis. SRC stromata were washed three times with PBS by centrifugation at 20,000 rpm in a Spinco 40S rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). Stroma-bound radioactivity was determined in a well-type gamma scintillation spectrometer.
Miscellaneous. All chemicals were of reagent grade. The sources and use of cobra venom and hydrazine have been previously cited (40 43 Table I for original latex fixation test and protein concentrations.) The negative control is IgM prepared from RF-negative NHS (----0). Lysis of SRC coated with R/A-Hem. In contrast to these results which do not show significant complement fixation by RF in free solution, some of the RF preparations readily induced lysis of SRC coated with R/A-IgG hemolysin in the presence of complement. SRC coated with various dilutions of R/A-Hem were incubated with constant amounts of two different polyclonal RF preparations and washed and incubated with complement. Fig. 1 shows that the two polyclonal RF preparations were able to sensitize REA for lysis by complement. The IgM (V.) prepared from NHS also sensitized the cells for lysis, but only in higher dilution due presumably to residual nonreduced hemolysin. At a 1: 200 dilution of R/A-IgG, greater than 80% lysis of the cells sensitized with polyclonal RF was observed, while the control gave less than 5% lysis. In subsequent experiments, REA were prepared with a 1: 500 dilution of R/A-Hem. The effect of diminishing amounts of two polyclonal RF on the ability to sensitize REA for lysis is shown in Fig. 2 (Fig. 3) . The correlation between hemolytic activity and hemagglutination titer was significant (P <0.01). Little difference between HuC and GPC was observed (Fig. 3) . Two monoclonal RF did not trigger hemolysis despite avid hemagglutinating activity. A third monoclonal RF (IgM Lay) was not reactive with rabbit IgG. Non-RF monoclonal IgM and normal human IgM (V.) neither agglutinated REA nor sensitized them for lysis by complement. Goat antirabbit IgG showed high hemolytic activity coupled with a low hemagglutination titer.
Lysis of tHEA. tHEA were also lysed by RF and complement. As shown, lysis was dependent on the amount of Agg-R/A-IgG used to coat the tanned cells (Fig. 4) . 200 ,Ag/ml were used routinely in subsequent experiments illustrated by Fig. 5 . There appeared to be a general correlation of hemolysis with agglutination titers. Two of the polyclonal RF produced 30-40% lysis. The three monoclonal RFs also induced 30-40% lysis, despite marked hemagglutinating activity. The non-RF monoclonal IgM and the V. of normal serum had low hemagglutinating activity and also low-grade hemolytic activity presumed to be nonspecific as a consequence of tannic acid treatment. This effect was not seen with the REA. Rabbit antihuman IgG induced marked lysis of tHEA, although its hemagglutination titer was not high. 13 15 FIGURE 5 Percent hemolysis of tHEA by IgM-RF and HuC is plotted versus RF titer determined with the same cells. Percent hemolysis correlates with RF titer for polyclonal RF (0) (r = 0.813, P < 0.01). In spite of high agglutination titer monoclonal RF (*) produce only slightly greater hemolysis than that associated nonspecifically with RF negative controls (0, [1) . The positive control, rabbit antihuman IgG (A), is strongly hemolytic although its agglutination titer is relatively low.
ways known to interfere with complement activity. The altered complement was employed for lysis of REA sensitized with polyclonal RF. These treatments included chelation of divalent cations with EDTA and EGTA, heat inactivation, and treatment with hydrazine and with cobra venom factor. Each of these prevented lysis (Fig. 6) C4, C3, C5, C6, and C8 included in the complement source were also highly inhibitory. In order to rule out complement depletion by immune complexes formed between complement components and the antisera as the reason for inhibition of lysis, anti-Clq, anti-C5, and anti-C6, and anti-C8 were reduced and alkylated. After this treatment which greatly impairs complement fixing potential, the antisera were able to inhibit lysis of RF-sensitized REA by complement. In addition, cells sensitized with REA were incubated with RF and HuC into which were incorporated trace amounts of 'I-labeled C3, C4, or C8, as outlined in Methods. Fig. 7 indicates that a good correlation was obtained between the binding of "SI-labeled C3, C4, or C8 and the percentage of lysis.
DISCUSSION
Complement fixation by IgM-RF remains a controversial subject despite many years of investigation. Early studies indicated that RF inhibited fixation of complement by IgG (16) (17) (18) (19) (20) . It was concluded that RF was incapable of complement activation and that it blocked the fixation of complement by IgG. A rational basis for this view was provided by the discovery that the antigenic site for RF (44, 45) and the binding site for the first component of complement, C1 (46), were both located on the Fc fragment of IgG. However, methodologic limitations made interpretation of many of these studies uncertain. In these reports aggregated IgC, which is highly anticomplementary, was used as antigen and whole hemolysin was used to sensitize SRC for titration of residual complement. Whole hemolysin contains both IgM and IgG anti-SRC antibody and since RF may react with IgG-sensitized SRC, these cells are not satisfactory indicator cells for titration of residual complement.
Reduction and alkylation of aggregated IgG markedly impairs its fixation of complement (47) . Using this antigen, Zvaifler and Schur obtained the first evidence of complement fixation by RF (11) . Subsequent studies reaffirmed these observations (12) but failed to provide incontrovertible proof that RF was responsible for the complement activation since whole serum was used as the source of RF and the possibility that some other non-RF anticomplementary substance was associated with the RF-IgG complexes was not excluded. SRC sensitized with whole hemolysin were used in titration of residual complement, further contributing to difficulty of interpreting experimental results. Tesar and Schmid extended and clarified these observations using purified RF and indicator cells sensitized with IgM hemolysin (13) . However, in all these reports RF proved an extremely weak complement-fixing antibody. Since IgM antibodies are generally quite effective in complement fixation (48) , some uncertainty remained.
In experiments reported here we were not successful in demonstrating any significant reduction of either whole hemolytic complement or individual complement components by RF-IgG complexes in fluid phase. However, it should be pointed out that we used considerably less aggregated IgG and RF than was used in the reports cited above. This was done because preparations of R/A-IgG are not totally incapable of fixing complement and we were concerned that further aggregation by RF of weakly complement-fixing IgG aggregates might account in part for the experimental results of other investigators.
In contrast, SRC sensitized with Agg-R/A-IgG or REA were readily hemolyzed by even small amounts of polyclonal RF in the presence of added complement. Three lines of evidence clearly indicate that hemolysis is mediated by complement. First, uptake of radiolabeled C4, C3, and C8 correlates directly with percent hemolysis. Secondly, hemolysis is abolished by chelation of divalent cations with EDTA or EGTA, treatment of complement with hydrazine or cobra venom, and by incubation of complement at 560C for 30 min. Thirdly, monospecific antisera reactive with individual complement components are highly inhibitory when added to the HuC source. The demonstration that uptake of the early complement component, C4, correlates directly with percent hemolysis and that hemolysis is inhibited by EGTA (49) and antisera to early com- (11, 12) , GPC is as effective as HuC in lysing the SRC sensitized with RF. Our findings are in agreement with the recent demonstration of complement fixation by RF reported by Tesar and Schmid (15) and contrast with the report of McDuffie and Brumfield (21) .
The direct hemolytic system described in this report for demonstration of complement fixation has proven considerably more sensitive than the fluid phase system. This is presumably because few molecules, probably only one, of cell-bound IgM-RF are needed to sensitize cells for lysis while multiple antibody molecules are needed in free solution to produce measurable complement reduction. These results are quite similar to those reported for IgM antibody specific for human blood group substance A (50) . A second advantage of the direct hemolytic system is that anticomplementary substances which may be present in RF preparations are removed by washing the cells before incubating them with complement.
While all polyclonal RF fixed complement in the direct hemolytic system, it is of interest that the three monoclonal RF did not. One of these RF was isolated by acid gel filtration which may have altered its ability to fix complement. None of the three was heated to 560C which has been reported to abolish anticomplementarity of mixed cryoglobulins (51) . Of course, our sample is small and other investigators have reported that some monoclonal RF are complement fixing (51) . However, it should be pointed out that none of those studies employed R/A-IgG and, therefore, one cannot differentiate complement fixation by RF from that produced by IgG in the mixed cryoprecipitate.
We have previously shown that efficiency of complement fixation by IgG antihapten antibody correlates directly with its binding energy (52) . Although there are only a few reported determinations of RF binding energies, they are all of similar magnitude (24, 25, (53) (54) (55) . A recent study suggests that while strength of RFIgG interaction may exert some influence on complement fixation it is probably of secondary importance (15) . It was shown that RF isolated from high-titer rheumatoid sera were more efficient in complement fixation than RF isolated from low-titer sera. (56) . In this regard, rabbits immunized with p-arsanilic acid conjugates have been clearly shown to produce IgM responses consisting of complement-fixing and noncomplement-fixing antibodies (57) .
Both complement-fixing and noncomplement-fixing monoclonal RF probably exist, although we believe that the latter are more frequently encountered. It is reasonable to assume that polyclonal RF represent the collective specificities and biological activities of many monoclonal RF, most of which do not fix complement. Thus, weakly complement-fixing polyclonal RF are composed of a low percentage of complement-fixing and a greater percentage of noncomplement-fixing IgM antibodies.
Noncomplement-fixing IgM may lack the C1 binding site or may possess configurations that interfere with C1 binding. Plaut, Cohen, and Tomasi have shown that pentameric Fc ,u is considerably more active on a molar basis with regard to complement fixation than is the parent IgM molecule from which it is derived (58) . This is consistent with the latter view stated above.
It is clear that antibody responses to some immunogens are restricted in immunoglobulin class and subclass (59, 60) . In certain experimental situations the mode of immunization is important (61 (7, 8) .
The direct hemolytic assay of RF described in this report is readily adaptable to whole serum and can be used to assess rapidly the complement-fixing activity of RF from large numbers of patients. This should provide important correlations with respect to the natural course of disease, and response to therapy in patients with rheumatoid arthritis.
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